Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the vaccine safeguards at-risk babies

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine works by activating the mother’s body’s defences to generate protective antibodies, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with instant defence from the point of delivery, exactly when they are most vulnerable to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.

• Nearly 85 per cent coverage when immunised four weeks before birth
• Maternal antibodies passed through placenta protect newborns from birth
• Protection achievable with 2-week gap before early delivery
• Vaccination in third trimester still provides significant infant protection

Strong evidence from the latest research

The efficacy of the pregnancy RSV vaccine has been confirmed through a extensive research programme undertaken in England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month timeframe, providing robust and representative data of the vaccine’s actual performance. The study’s results have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The breadth of this investigation gives healthcare professionals and expectant parents with assurance in the vaccine’s demonstrated effectiveness across different groups and contexts.

The results present a compelling picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV during the study period, with the vast majority being infants whose mothers had not received the vaccination. This stark contrast underscores the vaccine’s essential role in reducing the risk of serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.

Study methodology and scope

The research reviewed birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection levels and hospitalisations. The substantial sample size and thorough nature of the data gathering ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or small subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology assessed actual clinical results rather than experimental conditions, providing practical evidence of how the vaccine functions when given across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.

Understanding RSV and its hazards

Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.

The infection causes deep inflammation in the lungs and airways, making it extremely challenging for vulnerable newborns to breathe and feed properly. Parents commonly see their babies fighting for breath, their chests heaving as they attempt to draw enough air into their damaged lungs. Whilst most newborns recover with supportive care, a small but significant group succumb from RSV complications yearly, making prevention through vaccination a vital health service objective for safeguarding the most vulnerable and youngest members of society.

• RSV causes inflammation in lungs, resulting in severe breathing difficulties in infants
• Half of all infants contract the virus in their first few months of life
• Symptoms span from minor cold-like symptoms to life-threatening chest infections needing hospital treatment
• Over 20,000 UK infants require serious hospital care for RSV each year
• Small numbers of babies succumb to RSV complications each year in the UK

Take-up rates and expert recommendations

Since the RSV vaccine programme launched in 2024, health officials have highlighted the importance of pregnant women getting their jab at the optimal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that the timing is essential for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers approximately 85% protection, experts advise women to receive their vaccine as early as possible from 28 weeks of pregnancy forward to increase the antibodies transferred to their babies via the placenta.

The communication from public health bodies remains clear: pregnant women ought to prioritise vaccination during their final three months, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This flexible approach acknowledges the practical demands of pregnancy whilst maintaining strong safeguarding for at-risk infants during their most critical early months when RSV poses the greatest risk of severe infection.

Regional variations in vaccine uptake

Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Certain regions have attained greater immunisation rates among qualifying expectant mothers, whilst others continue working to boost understanding and availability of the jab. These geographical variations reflect variations in medical facilities, communication strategies, and local engagement efforts, though the national data shows robust and reliable protection irrespective of geographical location.

• NHS trusts rolling out varied communication campaigns to connect with expectant mothers
• Geographic variations in immunisation take-up in different parts of England necessitate strategic intervention
• Local healthcare systems modifying schemes to meet local requirements and situations

Real-world impact and parent viewpoints

The vaccine’s outstanding effectiveness translates into real advantages for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the launch of this safeguarding intervention, the 80% drop in admissions means thousands of infants shielded from serious illness. Parents no longer face the upsetting situation of seeing their babies gasping for air or struggle to eat, symptoms that characterise critical RSV illness. The vaccine has fundamentally shifted the landscape of neonatal breathing health, giving expectant mothers a preventative option to safeguard their most at-risk babies during those crucial first weeks.

For families like that of Malachi, whose acute RSV infection caused severe brain damage, the vaccine’s introduction carries deep personal significance. His mother’s advocacy for the jab emphasises the transformative consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now provided with protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to pregnant women during their third trimester, transforming what was once an predictable seasonal threat into a manageable health risk.